Leipzig was chosen as the location because a dynamic biotech cluster with strong research expertise has been established here. A key role is played by c-LEcta, a spin-out from Leipzig University, which was acquired by Kerry in 2022 and is now integrated into the centre.
Commercialised products from Kerry's biotech pipeline include an enzyme that removes acrylamide from instant coffee, a DNA removal solution for the production of vaccines and cell therapies, and baking enzymes that improve the shelf life and quality of baked goods.
With the new site, Kerry aims to strengthen its global biotechnology infrastructure and accelerate the development of sustainable nutrition strategies. Group CEO Edmond Scanlon emphasised that biotechnology is opening up a new wave of innovation for global markets and that Leipzig is now at the heart of this strategy.
News of "Kerry Group plc." from 24.09.2025